Ono Pharmaceutical Co., Ltd.
Clinical trials sponsored by Ono Pharmaceutical Co., Ltd., explained in plain language.
Japanese pharmaceutical company focused on oncology and immunology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to soothe agitation in Alzheimer's patients Results expected Dec 2026 (estimated)
- New hope for tough lymphoma: experimental drug ONO-4685 enters human testing Results expected Aug 2027 (estimated)
-
Daily pill takes aim at a rare brain disease that mimics Parkinson's
Disease control Not yet recruitingResearchers are testing an experimental oral drug called ONO-2808 in adults with the Parkinsonian subtype of multiple system atrophy (MSA-P), a rare and progressive brain disorder. The phase 3 trial enrolls about 486 people in the early stages of the disease, within five years of…
Phase 3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a new drug boost immunotherapy against Hard-to-Treat stomach cancer?
Disease control Not yet recruitingResearchers are testing whether adding an experimental drug called ONO-4578 to nivolumab and chemotherapy helps people with advanced or metastatic gastric cancer, esophagogastric junction cancer, or esophageal adenocarcinoma. The trial enrolls about 600 adults whose tumors are HE…
Phase 3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can an experimental injection ease the dryness and fatigue of Sjogren's?
Symptom relief Not yet recruitingResearchers are testing an experimental drug called ONO-4915 in adults with primary Sjogren's disease, a condition that causes dryness, fatigue, and pain. The trial enrolls about 60 people who have moderate to severe symptoms and a positive anti-SS-A/Ro antibody. Participants rec…
Phase 2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC